Cytostatic therapy, its value and indications in the management of prostatic carcinoma
Tóm tắt
Observations with cytostatic therapy of generalized prostatic carcinoma (PC) over 5 years are reported, cyclophosphamide (cpa) having been administered to hormone-resistant patients. A standard therapeutic and follow-up scheme, enabling the results to be assessed objectively, had been elaborated. Objective remission or stagnation, confirmed on this basis, was attained in 50%, relief of pain in 60% of the cases. Side effects were negligible. Withdrawal of cytostatics was required in 2 cases. The results indicate that secondary cytostatic therapy significantly potentiated the effect of hormone therapy in generalized PC, and in case of hormone resistance it offers the only chance of therapeutic benefit.
Tài liệu tham khảo
Druckrey, H., Steinhoff, D., Nakayama, M., Preussmann, R., Anger, K.: Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan.Dtsch. Med. Wochenschr., I:88, 651 (1963), II:88, 715 (1963).
Gibbons, R. P., Scott, W. W., Johnson, D. E., Prout, G. R., Schmidt, J. D., Gaeta, J., Saroff, J., Murphy, G. P., Joiner, J. R.: Prostatic carcinoma: Relationship between primary tumor, histologic grade and response to chemotherapy.Urology, 8, 222 (1976).
Leistenschneider, W., Nagel, R.: Zytostatische Therapie des Hormon- und Estracytresistenten Prostatakarzinoms mit Endoxan und 5-Fluorouracil als Tertiärbehandlung.Aktuel. Urol., 11, 143 (1980).
Muss, H. B., Howard, V., Richards, F., White, D. R., Jackson, D. V., Cooper, M. R., Stuart, J. J., Resnick, M. I., Brodkin, R., Spurr, C. L.: Cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer. A randomized trial.Cancer, 47, 1949 (1981).
Nagel, R., Leistenschneider, W.: Zytostatische Therapie des Prostatakarzinoms. Gegenwärtiger Stand und eigene Ergebnisse.Urologe [A],22, 304 (1983).
Schmidt, J. D., Scott, W. W., Gibbons, R., Johnson, D. E., Prout, G. R., Loening, S., Soloway, M., de Kernion, J., Pontes, J. F., Slack, N. H., Murphy, G. P.: Chemotherapy programs of the National Prostatic Cancer Project (NPCP).Cancer, 45, 1937 (1980).
Scott, W. W., Gibbons, R. P., Johnson, D. E., Prout, S. R., Schmidt, J. D., Saroff, J., Murphy, G. P.: The continued evaluation of the effect of chemotherapy in patients with advanced carcinoma of the prostate.J. Urol., 116, 211 (1976).
Slavik, M., Carter, S. D.: Single agents in prostatic cancer, a quick review (prepared for NPCP, G. P. Murphy chairman). Grant NoCA-14091-01 National Cancer Institute, National Institutes of Health, Bethesda, Maryland 1972.
Szendrői, Z., Balogh, F.: Der Prostatakrebs. Akadémiai Kiadó, Budapest 1965.
Weyrauch, H. M., Nesbit, J. O.: Use of triethylene-thiophosphamide (thio-TEPA) in treatment of advanced carcinoma of the prostate.J. Urol., 81, 185 (1985).
Yagoda, A.: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.Cancer, 32, 1131 (1973).